Long-Term Evolution of Kidney Function After Chimeric Antigen Receptor (CAR)-T Cell Therapy Infusion in Patients with Relapsed/Refractory Hematological Malignancies (R/RHM) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1252; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The most frequently utilized CART-cells constructs were axicabtagene ciloleucel(40%) and an investigational product(21.5%)...Steroids were required in 24 and tocilizumab in 23 patients...Conclusion AKI is relatively common; however, it is usually mild and resolves rapidly. Patients who develop AKI show worse kidney function after two years of follow-up."
Clinical • B Cell Lymphoma • Cardiovascular • Chronic Kidney Disease • Diabetes • Hematological Malignancies • Hypertension • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Metabolic Disorders • Non-Hodgkin's Lymphoma • Oncology
|
|
Abel Andrés Orelogio; Marc Patricio-Liébana; Gloria Iacoboni; Sheila Bermejo Garcia; Sara Nunez-Delgado; Natalia Ramos; Nestor Gabriel Toapanta Gaibor; Pere Barba; Maria Jose Soler; Juan Carlos León-Román
|